Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$1.60 USD
-0.02 (-1.23%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Actinium Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ATNM 1.60 -0.02(-1.23%)
Will ATNM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATNM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATNM
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
ATNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy
Other News for ATNM
Actinium Pharmaceuticals (ATNM) Showcases Promising Prostate Cancer Treatment Data
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer ...
Actinium Pharmaceuticals' ATNM-400 shows improved survival in prostate cancer
Promising Preclinical Results for ATNM-400 Drive Buy Rating for Actinium Pharmaceuticals
Actinium Pharma (ATNM) Rating Reaffirmed with Stable Price Target | ATNM Stock News